


Read & Publish Open Access initiative



Disease Models & Mechanisms



Launched in 2008, Disease Models & Mechanisms is an Open Access biomedical research journal that advances understanding of the mechanism, diagnosis and therapy of human disease.



Interdisciplinary in scope, Disease Models & Mechanisms covers a diverse range of diseases, including cancer, infectious diseases, developmental disorders, musculoskeletal disorders, and neurodegenerative and neurological diseases. Published research utilizes *in vitro* or *ex vivo* models, such as stem-cell-based models, organoids, patient material, model organisms, microorganisms, viruses and computational approaches.

In addition to research articles, Disease Models & Mechanisms features expert reviews, perspectives and interviews with leading scientists to address current and emerging themes in biomedical science.

Readership

Disease Models & Mechanisms aspires to connect and support all those working at every level of disease research, from basic researchers to clinicians at the forefront of patient care. Content is freely available to the journal's communities of basic and clinical researchers, those working for pharmaceutical companies, health professionals, patients and their advocates and families.

Abstracting and indexing services

Disease Models & Mechanisms is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment

DMM has been awarded the Directory of Open Access Journals seal – given to journals that achieve a high level of openness, adhere to best practice and have high publishing standards. The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals are included in our Read & Publish Open Access agreements.

Key metrics

- 2022 Impact Factor: 4.3
- Five-year Impact Factor: 5.1
- Two-year citation median: 3.0
- Eigenfactor score: 0.00806
- Article Influence Score: 1.73589
- Immediacy Index: 1.4
- h-index: 99
- Scopus: 7.5
- SJR indicator: 1.489
- SNIP: 0.979



Disease Models & Mechanisms

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

- E. Elizabeth Patton (MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK)

Deputy Editor-in-Chief

- Elaine R. Mardis (Nationwide Children's Hospital, Ohio, USA)

Editors

- James Amatruda (Children's Hospital Los Angeles, CA, USA)
- Steven J. Clapcote (University of Leeds, UK)
- Tatsushi Igaki (Kyoto University, Japan)
- Monica J. Justice (The Hospital for Sick Children [SickKids], Toronto, Canada)
- Vivian Li (The Francis Crick Institute, London, UK)
- Karen Liu (King's College London, UK)
- Owen Sansom (Beatson Institute for Cancer Research, Glasgow, UK)
- David M. Tobin (Duke University School of Medicine, Durham, NC, USA)

Associate Editors

- Sally Dunwoodie (Victor Chang Cardiac Research Institute, Australia)
- Monkol Lek (Yale School of Medicine, USA)
- Sumana Sanyal (University of Oxford, UK)
- Ian Smyth (Monash University, Australia)
- Eckhard Wolf (Gene Center, LMU Munich, Germany)

What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“DMM is well respected in my field and I was delighted to publish our research here. Alongside being a publisher, The Company of Biologists do a stellar job in their support of the scientific community. The Read & Publish agreement with University of Sheffield makes it even more attractive to publish in this collection of journals, allowing immediate Open Access for all.”

Dr Phil Elks, University of Sheffield, UK

Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Read & Publish: number of participating institutions



Figures based on the latest available data from Impact Vizor and Altmetric Explorer

biologists.com/read-publish

